<DOC>
	<DOCNO>NCT01149720</DOCNO>
	<brief_summary>This Phase 1 , randomize , open label , 2 treatment , 2 period , 2-way crossover study , extension phase design steady state PK ARQ 197 investigate use tablet administer fed state ( test treatment ) capsule administer least 1 hour 2 hour meal ( reference treatment ) subject advanced solid tumor .</brief_summary>
	<brief_title>Determination Relative Bioavailability ARQ 197 Tablet Formulation With Capsule C Formulation Reference Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Subjects must histologically cytologically confirm advanced solid tumor screening . Male female equal great 18 year age . All female subject childbearing potential must negative serum pregnancy test result initiate study treatment . An Eastern Cooperative Oncology Group ( ECOG ) performance status equal le 2 Adequate bone marrow , liver , renal function , define : Platelet count equal great 75 x 10 ( 9 ) /L Hemoglobin ( Hb ) equal great 9.0 g/dL Absolute neutrophil count ( ANC ) equal great 1.5 x 10 ( 9 ) /L Total bilirubin equal less 1.5 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) equal less 3 x ULN ( equal less 5 x ULN subject liver metastasis ) Serum creatinine equal less 1.5 x ULN History cardiac disease : Active coronary artery disease ( CAD ) , define myocardial infarction ( MI ) , unstable angina , coronary bypass graft ( CABG ) , stenting within 6 month prior study entry ( MI occur &gt; 6 month prior study entry permit ) Evidence uncontrolled bradycardia cardiac arrhythmia define equal great Grade 2 accord NCI CTCAE , version 4.0 , uncontrolled hypertension Active , clinically serious infection ( ) define equal great Grade 2 accord NCI CTCAE , version 4.0 . Known metastatic brain meningeal tumor , unless subject &gt; 3 month definitive therapy clinically stable ( supportive therapy steroid anticonvulsant medication allow ) respect tumor time first dose study drug . Prior therapy mesenchymalepithelial transition factor ( cMET ) inhibitor , include ARQ 197 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>ARQ 197</keyword>
</DOC>